Full Breakdown
Xenon Pauses Psychiatry Trials Amid Neuropsychiatric Events, Keeps Epilepsy Momentum
By Drooid · · How we work
Core Development: Voluntary Halt of Depression and Bipolar Trials
On September 17, Xenon Pharmaceuticals announced a precautionary pause on enrolling new patients in its Phase 3 studies of azetukalner for major depressive disorder (MDD) and bipolar depression. The decision followed a review with the company’s Data Safety Monitoring Board that identified neuropsychiatric adverse events—including confusion, speech difficulties, ataxia and a “very small number” of psychosis cases. Patients already enrolled will continue treatment, and the company will assess dosing modifications before resuming recruitment. The pause does not affect ongoing epilepsy programs or the New Drug Application (NDA) for azetukalner in focal seizures.
Background & Context
Azetukalner, a Kv7 potassium-channel opener, has shown strong efficacy in epilepsy, delivering a 42.7 % placebo-adjusted reduction in median monthly seizure frequency in the Phase 3 X-TOLE2 trial. The drug’s safety profile in epilepsy is supported by more than 1,500 patient-years of data. Building on these results, Xenon filed an NDA with the U.S. Food and Drug Administration (FDA) for focal seizures, positioning the company for its first product launch.
Data & Statistics
- Share price fell between 23 % and 30 % after the pause was disclosed.
- The MDD trial (X-NOVA2) had enrolled roughly 360 participants, about 80 % of its 450-patient target, when enrollment stopped.
- In epilepsy, the Phase 2b X-TOLE and Phase 3 X-TOLE2 studies together contributed >1,500 patient-years of safety exposure.
- Seizure efficacy: a 53.2 % median reduction in seizures (12-week, 25 mg daily dose) and a 42.7 % placebo-normalized improvement in monthly seizure frequency.
Official Statements & Responses
Chief Executive Officer Ian Mortimer described the pause as “temporary” and said the interval will be used to explore dosing adjustments. He noted that the epilepsy NDA process will continue, with an FDA decision expected in September 2027. The company highlighted its cash position (USD 1.245 billion as of June 30) to fund further investigations.
Conflicting Reports & Gaps
Sources differ on the exact magnitude of the stock decline, ranging from 23 % to 30 %. No public data have been released detailing the precise incidence rates of each neuropsychiatric event across the depression and bipolar trials, nor are patient-level risk factors identified. The timing of when enrollment might resume remains unspecified beyond the planned topline readout in the first quarter of 2027.
Verbatim Quotes
- “If you look at other drugs that are used for depression, they do cause serious adverse events, sometimes in keeping with this along the lines of psychosis, sometimes other issues,” — Chris Kenney, chief medical officer.
- “Our NDA submission is a significant milestone for Xenon as we continue to work toward the potential approval and launch of our first product,” — Ian Mortimer, chief executive.
- “In a very small number of patients, we have seen an adverse event captured under the broad preferred term of psychosis.” — Chris Kenney.
What’s Next
Xenon will complete six-week dosing for the 360 participants already in the MDD study and unblind the data, with topline results expected in the first quarter of 2027. Dosing-modification strategies will be evaluated, and any necessary updates will be filed with the FDA. The focal-seizure NDA will proceed toward an FDA decision in September 2027, keeping the epilepsy indication as the primary growth driver while the psychiatric program remains on hold.
